{"entity":{"id":"measurement-to-benefit-evidence","kind":"term","name":"Evidence from measurement to patient benefit","aka":[],"tldr":"A reliable measurement, a biological explanation and a useful treatment decision each need evidence. This map helps readers identify which part of a claim has actually been tested.","summary":"A useful reading framework follows the observation through its interpretation, mechanism, intervention and patient outcome. These are questions to examine, not a mandatory experimental sequence. An accurate assay can measure a marker that does not predict treatment benefit; a compound can bind a protein without proving that its effect depends on that protein. A model can reproduce an experiment without predicting an outcome in people. Each linked concept identifies a different evidence boundary and the source supporting it.","asOf":"2026-11-10","links":[{"label":"FDA: biomarkers, roles and qualification","url":"https://www.fda.gov/drugs/biomarker-qualification-program/about-biomarkers-and-qualification"},{"label":"Cellular target-engagement study (2013)","url":"https://doi.org/10.1126/science.1233606"},{"label":"Clinical actionability framework (2018)","url":"https://doi.org/10.1093/annonc/mdy263"},{"label":"Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework.","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6938631/"},{"label":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).","url":"https://pubmed.ncbi.nlm.nih.gov/30137196/"},{"label":"FDA: oncology clinical-trial endpoints (2018)","url":"https://www.fda.gov/media/71195/download"}],"tags":[],"related":["antigen-expression-and-response","binding-site-barrier","antibody-internalization-trafficking","lysosomal-payload-egress","drug-target-engagement","experimental-versus-clinical-exposure","prognostic-versus-predictive-biomarkers","functional-variant-evidence","blood-cell-variants-liquid-biopsy","ctdna-shedding-negative-results","detection-versus-quantification","finite-molecule-sampling","tumor-informed-assay-design","biomarker-qualification-context","test-agreement-versus-accuracy","growth-rate-inhibition","cytostasis-versus-cell-death","on-target-drug-validation","model-context-of-use","confounding-by-indication","immortal-time-bias","target-trial-emulation","competing-risks","trial-population-transportability","biomarker-cutpoint-selection","decision-curve-net-benefit","inconclusive-and-negative-evidence","analytical-vs-clinical-validation","cancer-drivers-vs-actionable"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["A variant-based treatment claim contains several separate claims: the sequence finding is real, it changes biology, that biology creates a relevant drug response, and treatment improves outcomes in people. This is a way to examine evidence, not a mandatory experimental sequence or a claim that every effective medicine starts with a mutation. Consider a fictional report with a supported sequence change relative to a reference, an untested activating prediction, a lower pathway signal after drug exposure, unchanged cell growth and no matched clinical comparison. Variant calling supports the sequence observation; effect prediction supplies a hypothesis. The experiment shows a biochemical drug effect under its conditions, not verified action on the intended target, growth dependence or patient benefit. Unchanged growth also does not settle every possible drug effect; exposure, timing and assay sensitivity matter. No exposure value or clinical effect size follows from these qualitative observations.","Expression and controlled functional evidence for the exact alteration can strengthen a biological interpretation; another alteration in the same gene may behave differently. Perturbation with rescue or complementary controls can test dependence, because an active pathway need not be necessary for growth. A drug-effect claim needs relevant exposure and evidence that the compound reaches and interacts with its intended target; other drug actions or failure to reach tumour remain possible. Activation, loss of function and high protein abundance do not all imply that inhibiting the named protein will help. Other cells, parallel pathways and treatment history can change that hypothesis. A protein-only construct may miss RNA-processing effects, so a normal assay is not proof that a variant is harmless. Brnich's functional-classification recommendations address assay relevance; Mateo's actionability framework separately distinguishes relevant human, adjacent clinical and preclinical evidence. Neither framework turns pathogenicity into drug sensitivity or an evidence grade into treatment access. Repeated predictions may share data or assumptions and are not independent experiments.","Each claim needs its own measurement. Sequence identity, specimen, assay version, controls and interpretation establish what was tested. Altered-transcript proportion, normalised protein activity, cell growth at a defined exposure and participant response rate have different units and meanings; combining them into one score can hide those differences. Target engagement is separate from downstream change, cancer-cell death, tumour response and survival. At the clinical step, disease, biomarker, treatment setting and comparator must match the claim, with outcome definition, follow-up, harms and uncertainty retained. A biochemical signal alone does not establish clinical benefit, eligibility, availability or an individual's outcome. The model above is fictional, and the FDA's dated 2018 endpoint guidance is used for these outcome distinctions."],"category":"Methods and models"},"route":"/terms/measurement-to-benefit-evidence/","neighbours":{"term":[{"id":"cancer-drivers-vs-actionable","kind":"term","name":"Actionable genomic biomarkers","route":"/terms/cancer-drivers-vs-actionable/"},{"id":"analytical-vs-clinical-validation","kind":"term","name":"Analytical versus clinical validation","route":"/terms/analytical-vs-clinical-validation/"},{"id":"antibody-internalization-trafficking","kind":"term","name":"Antibody internalization and intracellular trafficking","route":"/terms/antibody-internalization-trafficking/"},{"id":"antigen-expression-and-response","kind":"term","name":"Antigen expression and treatment response","route":"/terms/antigen-expression-and-response/"},{"id":"binding-site-barrier","kind":"term","name":"Binding-site barrier in tumor delivery","route":"/terms/binding-site-barrier/"},{"id":"biomarker","kind":"term","name":"Biomarker","route":"/terms/biomarker/"},{"id":"biomarker-cutpoint-selection","kind":"term","name":"Biomarker cutoff selection and validation","route":"/terms/biomarker-cutpoint-selection/"},{"id":"biomarker-qualification-context","kind":"term","name":"Biomarker qualification and context of use","route":"/terms/biomarker-qualification-context/"},{"id":"blood-cell-variants-liquid-biopsy","kind":"term","name":"Blood-cell variants in liquid biopsy","route":"/terms/blood-cell-variants-liquid-biopsy/"},{"id":"competing-risks","kind":"term","name":"Competing events and cumulative incidence","route":"/terms/competing-risks/"},{"id":"confounding-by-indication","kind":"term","name":"Confounding by indication","route":"/terms/confounding-by-indication/"},{"id":"model-context-of-use","kind":"term","name":"Context of use for a tumor model","route":"/terms/model-context-of-use/"},{"id":"decision-curve-net-benefit","kind":"term","name":"Decision curves and net benefit","route":"/terms/decision-curve-net-benefit/"},{"id":"detection-versus-quantification","kind":"term","name":"Detection and quantification limits","route":"/terms/detection-versus-quantification/"},{"id":"drug-target-engagement","kind":"term","name":"Drug target engagement","route":"/terms/drug-target-engagement/"},{"id":"experimental-versus-clinical-exposure","kind":"term","name":"Experimental and clinical drug exposure","route":"/terms/experimental-versus-clinical-exposure/"},{"id":"finite-molecule-sampling","kind":"term","name":"Finite-molecule sampling in blood tests","route":"/terms/finite-molecule-sampling/"},{"id":"functional-variant-evidence","kind":"term","name":"Functional evidence for a sequence variant","route":"/terms/functional-variant-evidence/"},{"id":"cytostasis-versus-cell-death","kind":"term","name":"Growth arrest, cell number and cell death","route":"/terms/cytostasis-versus-cell-death/"},{"id":"growth-rate-inhibition","kind":"term","name":"Growth-rate correction in drug-response assays","route":"/terms/growth-rate-inhibition/"},{"id":"immortal-time-bias","kind":"term","name":"Immortal time bias","route":"/terms/immortal-time-bias/"},{"id":"inconclusive-and-negative-evidence","kind":"term","name":"Inconclusive results and evidence against an effect","route":"/terms/inconclusive-and-negative-evidence/"},{"id":"lysosomal-payload-egress","kind":"term","name":"Lysosomal payload transport","route":"/terms/lysosomal-payload-egress/"},{"id":"on-target-drug-validation","kind":"term","name":"On-target validation of drug effects","route":"/terms/on-target-drug-validation/"},{"id":"prognostic-versus-predictive-biomarkers","kind":"term","name":"Prognostic and predictive biomarkers","route":"/terms/prognostic-versus-predictive-biomarkers/"},{"id":"target-trial-emulation","kind":"term","name":"Target-trial emulation","route":"/terms/target-trial-emulation/"},{"id":"test-agreement-versus-accuracy","kind":"term","name":"Test agreement and diagnostic accuracy","route":"/terms/test-agreement-versus-accuracy/"},{"id":"trial-population-transportability","kind":"term","name":"Transporting trial evidence to another population","route":"/terms/trial-population-transportability/"},{"id":"ctdna-shedding-negative-results","kind":"term","name":"Tumor DNA shedding and negative plasma results","route":"/terms/ctdna-shedding-negative-results/"},{"id":"tumor-informed-assay-design","kind":"term","name":"Tumor-informed and tumor-naive assay design","route":"/terms/tumor-informed-assay-design/"}]}}